Anna Banerji

1

Article

3

Comments
  • Associate Professor Pediatrics and Dalla Lana School of Public Health, Chair Indigenous Health Conference, North American Refugee Health Conference, University of Toronto
Healthy, full-term Inuit babies are not eligible for palivizumab even though they have four to 10 times the rate of hospital admission compared to “high-risk” infants. (Philippe Put/flickr)

Inuit infants need access to medication to prevent respiratory illness

Anna Banerji, University of Toronto; David Suzuki, University of British Columbia, and Faisal Moola, University of Guelph

A drug called palivizumab can keep babies infected with respiratory syncytial virus (RSV) out of the hospital, but many Inuit babies, who have a higher risk of infection, are not getting it.

Contact Anna for

  • General
  • Media request
  • Speaking request
  • Consulting / Advising
  • Research collaboration
  • Research supervision